N-MOmentum phase II/III pivotal trial of Uplizna in Neuromyelitis Optica Spectrum Disorder.

The post-hoc analysis represents the experience of 75 people with AQP4 antibody positive NMOSD who were treated with Uplizna for four or more years during the open-label extension period of the N-MOmentum trial. The study shows a total of 18 attacks occurred in 13 people, with an annualized attack rate of 0.052 attacks per person year. The small number of total attacks decreased significantly after the first year of treatment with Uplizna. It shows 67% of attacks occurred within the first year (12 attacks) and that 92% of patients were attack-free in subsequent years (two attacks each during years two to four).

The infection rate did not increase over time on treatment with Uplizna. Finally Uplizna was generally well tolerated, with few treatment-related dose interruptions and no treatment discontinuations. These data are published in the Multiple Sclerosis Journal.

See: "Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for at least 4?years in the N-MOmentum trial." Mary Rensel et al. Multiple Sclerosis Journal Published October 1, 2021 https://doi.org/10.1177/13524585211047223